Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $3.4 million.

  • Fulcrum Therapeutics' Share-based Compensation fell 1197.28% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 2348.96%. This contributed to the annual value of $14.6 million for FY2024, which is 167.54% down from last year.
  • According to the latest figures from Q3 2025, Fulcrum Therapeutics' Share-based Compensation is $3.4 million, which was down 1197.28% from $2.9 million recorded in Q2 2025.
  • Fulcrum Therapeutics' 5-year Share-based Compensation high stood at $4.3 million for Q2 2024, and its period low was $2.1 million during Q1 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $3.4 million (2025), whereas its average is $3.3 million.
  • In the last 5 years, Fulcrum Therapeutics' Share-based Compensation skyrocketed by 12617.77% in 2021 and then plummeted by 3381.68% in 2025.
  • Over the past 5 years, Fulcrum Therapeutics' Share-based Compensation (Quarter) stood at $3.8 million in 2021, then dropped by 13.76% to $3.3 million in 2022, then rose by 5.44% to $3.4 million in 2023, then dropped by 28.18% to $2.5 million in 2024, then skyrocketed by 35.65% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, $2.9 million for Q2 2025, and $3.2 million during Q1 2025.